{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:50:00Z","timestamp":1785912600967,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003429.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000}}],"reference-count":118,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003429.pub5","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T11:14:52Z","timestamp":1755774892000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously untreated or minimally treated children with hemophilia A or B"],"prefix":"10.1002","volume":"2025","author":[{"given":"Elham","family":"Razmpoosh","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact (HEI); McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omotola O","family":"Olasupo","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact (HEI); McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Department of Pediatrics; McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Matino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-8766","authenticated-orcid":false,"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact (HEI); McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD003429.pub5-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"7","key":"10.1002\/14651858.CD003429.pub5-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/MPH.0b013e318068b1d6","article-title":"Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy","volume":"29","author":"Hacker","year":"2007","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"Suppl","key":"10.1002\/14651858.CD003429.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"Abstract 3","DOI":"10.1182\/blood.V106.11.3.3","article-title":"Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency","volume":"106","author":"Manco-Johnson","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD003429.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003429.pub5-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1046\/j.1365-2516.9.s1.15.x","article-title":"North American prophylaxis studies for persons with severe haemophilia: background, rationale and design","volume":"9","author":"Manco-Johnson","year":"2003","journal-title":"Haemophilia"},{"issue":"21","key":"10.1002\/14651858.CD003429.pub5-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V122.21.210.210","article-title":"Long-term orthopedic effects of delaying prophylaxis in severe hemophilia A until age 6 years: results of the Joint Outcome Study Continuation (JOSc)","volume":"122","author":"Manco-Johnson","year":"2013","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/hae.12400","article-title":"What is the cost of delaying prophylaxis until the school years? Results from the Joint Outcome Study Continuation Project","volume":"20","author":"Manco-Johnson","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0008|cit8","unstructured":"Joint Outcome Study continuation for children with severe factor VIII deficiency https:\/\/clinicaltrials.gov\/show\/NCT01000844"},{"issue":"23","key":"10.1002\/14651858.CD003429.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V126.23.2289.2289","article-title":"Non-factor VIII coagulation proteins fail to predict joint outcome in severe hemophilia A","volume":"126","author":"Warren","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD003429.pub5-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/hae.13778","article-title":"Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes","volume":"25","author":"Warren","year":"2019","journal-title":"Haemophilia"},{"issue":"11","key":"10.1002\/14651858.CD003429.pub5-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/hae.12400","article-title":"Low-dose factor VIII prophylaxis in children with severe hemophilia","volume":"20","author":"Verma","year":"2014","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/hae.12838","article-title":"A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia \u2013 a success story from a resource limited country","volume":"22","author":"Verma","year":"2016","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD003429.pub5-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s12288-013-0302-z","article-title":"Low dose factor VIII prophylaxis in children with severe hemophilia","volume":"29","author":"Verma","year":"2013","journal-title":"Indian Journal of Hematology & Blood Transfusion"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2141.1976.tb00973.x","article-title":"Prophylaxis in haemophilia: a double-blind controlled trial","volume":"33","author":"Aronstam","year":"1976","journal-title":"British Journal of Haematology"},{"issue":"21","key":"10.1002\/14651858.CD003429.pub5-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1182\/BLOODADVANCES.2020002789","article-title":"The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia","volume":"4","author":"Bertolet","year":"2020","journal-title":"Blood Advances"},{"issue":"9","key":"10.1002\/14651858.CD003429.pub5-BIB0017|cit17","first-page":"2428","article-title":"A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group","volume":"83","author":"Bray","year":"1994","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003429.pub5-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1002\/ajh.26841","article-title":"Neurocognitive and neurological outcomes in children with hemophilia B are unaffected by long-term exposure to nonacog beta pegol (N9-GP)","volume":"98","author":"Carcao","year":"2023","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0019|cit19","unstructured":"Research trial to study inhibitor development in previously untreated or minimally exposed children to two different commercially available types of factor VIII https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2009\/091\/001059"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0020|cit20","first-page":"68","article-title":"Effect of low dose prophylaxis versus episodic treatment on joint events in severe hemophilia A patients above 2 years: a randomized open label pilot study in Eastern India","volume":"34","author":"Chakraborty","year":"2018","journal-title":"Indian Journal of Hematology & Blood Transfusion"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003429.pub5-BIB0021|cit21","first-page":"460","article-title":"A new treatment concept for haemophilia: safety, pharmacokinetics and pharmacodynamics of single i.v. and s.c. doses of a monoclonal anti-TFPI antibody in healthy males and haemophilia subjects","volume":"11","author":"Chowdary","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/jth.12993","article-title":"Improved health-related quality of life (QoL) of haemophilia B patients treated with a weekly 40 IU kg-1 dose of a new long-acting recombinant factor IX (FIX) product, nonacog beta pegol","volume":"13","author":"Chowdary","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/hae.13478","article-title":"Low-dose prophylaxis versus on-demand treatment in Indonesian children with severe hemophilia A: an interim report","volume":"24","author":"Chozie","year":"2018","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD003429.pub5-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/hae.13770","article-title":"Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children","volume":"25","author":"Chozie","year":"2019","journal-title":"Haemophilia"},{"issue":"2 Suppl 4","key":"10.1002\/14651858.CD003429.pub5-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/s0037-1963(01)90109-x","article-title":"Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients","volume":"38","author":"Courter","year":"2001","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0026|cit26","unstructured":"A study to assess whether factor VIII given once a week will prevent major bleeds in severe hemophilia A https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2014\/12\/005277"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0027|cit27","unstructured":"Prophylactic therapy in hemophilia https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2018\/08\/015235"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003429.pub5-BIB0028|cit28","first-page":"209","article-title":"Correlation between oxidative stress and biomarkers of joint damage in patients with severe haemophilia treated by different prophylaxis regimens","volume":"99","author":"Djunic","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD003429.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1055\/s-0038-1650635","article-title":"Radiological score in paediatric haemophilic patients with early and late onset of factor VIII \u2013 prophylaxis","volume":"76","author":"Dzinaj","year":"1996","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0030|cit30","unstructured":"A study to compare the difference in effect between treating bleeds after they occur or giving preventative treatment on an ongoing basis, also to determine levels of factor VIII in the blood following treatment in children with hemophilia A https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-005575-17-AT"},{"issue":"6","key":"10.1002\/14651858.CD003429.pub5-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study","volume":"4","author":"Feldman","year":"2006","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"fmac039","DOI":"10.1093\/tropej\/fmac039","article-title":"Twice weekly vs. thrice weekly low-dose prophylactic factor VIII therapy in children with hemophilia A: an open label randomized trial","volume":"68","author":"Gomber","year":"2022","journal-title":"Journal of Tropical Pediatrics"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0033|cit33","first-page":"409","article-title":"Efficacy and safety of prophylaxis in previously untreated patients with severe hemophilia A in Iran","volume":"100","author":"Karimi","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/MPH.0000000000001082","article-title":"Modified primary prophylaxis in previously untreated patients with severe hemophilia A in Iran","volume":"40","author":"Karimi","year":"2018","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"11","key":"10.1002\/14651858.CD003429.pub5-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1016\/j.jtha.2023.07.030","article-title":"The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results","volume":"21","author":"Kenet","year":"2023","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1046\/j.1365-2516.2003.00751.x","article-title":"Prophylaxis in factor IX deficiency product and patient variation","volume":"9","author":"Kisker","year":"2003","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1046\/j.1365-2516.1998.440413.x","article-title":"When should prophylactic treatment in patients with haemophilia A and B start? The German experience","volume":"4","author":"Kreuz","year":"1998","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1160\/th03-10-0643","article-title":"Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation","volume":"93","author":"Kreuz","year":"2005","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0039|cit39","unstructured":"Ledger KS Bensen-Kennedy D Backman N Veldman A Clinical decision making is effective in reducing bleeding rates without the need to monitor FVIII trough levels to patients with severe hemophilia A receiving prophylaxis with rVIII-single chain 62nd Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; 2016 May 25-28; Montpellier, France 10.1111\/jth.13325"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0040|cit40","unstructured":"Lemons R Wang M Curtin J Huth-Kuehne A Lepatan L Male C Safety and efficacy of recombinant factor IX fusion protein (rIX-FP) in previously untreated patients with hemophilia B Research and Practice in Thrombosis and Haemostasis 2022 6 10.1002\/rth2.12787"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V128.22.327.327","article-title":"Inhibitor development in previously untreated patients with severe hemophilia A treated with Nuwiq, a new generation recombinant FVIII of human origin","volume":"128","author":"Liesner","year":"2016","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003429.pub5-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/hae.12625","article-title":"3-year analyses from spinart: patient-and joint-level changes in magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand","volume":"21","author":"Lundin","year":"2015","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD003429.pub5-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/hae.14315","article-title":"Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B","volume":"27","author":"Mahlangu","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD003429.pub5-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/bloodadvances.2022007529","article-title":"The safety and efficacy of N8-GP (Turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A","volume":"7","author":"Male","year":"2023","journal-title":"Blood Advances"},{"issue":"6","key":"10.1002\/14651858.CD003429.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2516.2011.02495.x","article-title":"Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE) \u2013 an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A","volume":"17","author":"Martinowitz","year":"2011","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1600-0609.1976.tb01115.x","article-title":"Evaluation of prophylactic replacement therapy in haemophilia B","volume":"16","author":"Morfini","year":"1976","journal-title":"Scandinavian Journal of Haematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003429.pub5-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/hae.13666","article-title":"Design of a phase 3, prospective, multicenter, open-label study of safety and hemostatic efficacy of rurioctocog alfa pegol in previously untreated patients <6 years of age with severe hemophilia A","volume":"25","author":"Mullins","year":"2019","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003429.pub5-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/rth2.12393","article-title":"Final results of pups B-long study: evaluating safety and efficacy of rFIXFc in previously untreated patients with haemophilia B","volume":"4","author":"Nolan","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"i63","DOI":"10.1093\/qjmed\/hcy200.137","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"111","author":"Elalfy","year":"2018","journal-title":"QJM: Monthly Journal of the Association of Physicians"},{"issue":"21","key":"10.1002\/14651858.CD003429.pub5-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Pocoski J Kim B Humphries TJ Hong W Regional differences in patient-reported outcomes in a study of adult prophylaxis versus on-demand treatment with Bayer's sucrose-formulated recombinant factor VIII: 3-year data from Spinart Blood 2014 124 21","DOI":"10.1182\/blood.V124.21.1518.1518"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/jth.12993","article-title":"A phase III, open-label, multicentre study to evaluate efficacy and safety of a plasma-derived von Willebrand factor\/factor VIII concentrate in pediatric subjects with hemophilia A (Swiftly-HA study)","volume":"13","author":"Pompa","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"24","key":"10.1002\/14651858.CD003429.pub5-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1365-2516.2011.02550.x","article-title":"Phase III randomized, controlled trial of pre-emptive vs. standard prophylaxis to prevent inhibitor formation in children with severe hemophilia A: the INHIBIT study","volume":"17","author":"Ragni","year":"2011","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003429.pub5-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/jth.12993","article-title":"Spinart trial 3-year results with Bayer's sucrose formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis","volume":"13","author":"Reding","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"21","key":"10.1002\/14651858.CD003429.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1182\/blood.V120.21.4628.4628","article-title":"Evaluation of two secondary prophylaxis regimens of recombinant factor ix(r-ix) in moderately severe to severe (fix <=2%) hemophilia B patients","volume":"120","author":"Rendo","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD003429.pub5-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/hae.13466","article-title":"Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: two open-label studies","volume":"24","author":"Rusen","year":"2018","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1600-0609.1977.tb01528.x","article-title":"Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study","volume":"30","author":"Schimpf","year":"1977","journal-title":"Scandinavian Journal of Haematology. Supplementum"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1160\/th07-06-0417","article-title":"Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study","volume":"99","author":"Schobess","year":"2008","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/hae.12305","article-title":"Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy","volume":"20","author":"Shafer","year":"2014","journal-title":"Haemophilia"},{"issue":"2","key":"10.1002\/14651858.CD003429.pub5-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1182\/blood-2004-06-2283","article-title":"The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B","volume":"105","author":"Shapiro","year":"2005","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003429.pub5-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1182\/blood-2021-146126","article-title":"Immunogenicity, efficacy and safety of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from an open-label multicenter clinical trial","volume":"138","author":"Sidonio","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003429.pub5-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1182\/blood-2021-146143","article-title":"Rurioctocog alfa pegol use in immune tolerance induction: interim results from an open-label multicenter clinical trial in previously untreated patients with severe hemophilia A","volume":"138","author":"Sidonio","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD003429.pub5-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/17474086.2023.2247160","article-title":"Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study","volume":"16","author":"Sidonio","year":"2023","journal-title":"Expert Review of Hematology"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.thromres.2015.10.014","article-title":"Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF\/FVIII concentrate (VONCENTO) in subjects with haemophilia A (SWIFT-HA study)","volume":"137","author":"Skotnicki","year":"2016","journal-title":"Thrombosis Research"},{"issue":"4","key":"10.1002\/14651858.CD003429.pub5-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/jth.13647","article-title":"Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial","volume":"15","author":"Stasyshyn","year":"2017","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1160\/TH14-05-0407","article-title":"Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study","volume":"114","author":"Tagliaferri","year":"2015","journal-title":"Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12185-018-2499-y","article-title":"Inhibitor development, safety, and efficacy of Advate(\u00ae) in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan","volume":"109","author":"Taki","year":"2019","journal-title":"International Journal of Hematology"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1365-2516.2012.02820.x","article-title":"Tailored primary prophylaxis with dose-escalation in Iranian hemophilia A","volume":"18","author":"Tehrani","year":"2012","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003429.pub5-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1538-7836.2011.04380_2.x","article-title":"A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B","volume":"9","author":"Valentino","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/hae.12344","article-title":"Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects","volume":"20","author":"Valentino","year":"2014","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1046\/j.1365-2141.2001.02580.x","article-title":"Long-term outcome of individualized prophylactic treatment of children with severe haemophilia","volume":"112","author":"den Berg","year":"2001","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0073|cit73","first-page":"1","article-title":"Prophylaxis with once, twice or three-times weekly dosing of rFVIII-FS prevents joint bleeds in a previously treated pediatric population with moderate\/severe hemophilia A","volume":"3","author":"Vdouin","year":"2011","journal-title":"Journal of Coagulation Disorders"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/hae.12083","article-title":"Clinical study to investigate the immunogenicity, efficacy and safety of treatment with human-cl rhFVIII in previously untreated patients with severe haemophilia A","volume":"19","author":"Walter","year":"2013","journal-title":"Haemophilia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003429.pub5-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/hae.12400","article-title":"A quality of life study (CHO-KLAT) of boys with severe hemophilia A in China: a comparison of on-demand to short-term prophylaxis","volume":"20","author":"Wu","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2147\/TCRM.S243146","article-title":"Safety and efficacy of Turoctocog alfa in the prevention and treatment of bleeding episodes in previously treated patients from China with severe hemophilia A: results from the guardian 7 trial","volume":"16","author":"Wu","year":"2020","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"6","key":"10.1002\/14651858.CD003429.pub5-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1111\/hae.14652","article-title":"Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients","volume":"28","author":"Xi","year":"2022","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/hae.13883","article-title":"Safety and efficacy of Turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: results from the guardian 4 multinational clinical trial","volume":"26","author":"Yaish","year":"2020","journal-title":"Haemophilia"},{"issue":"2","key":"10.1002\/14651858.CD003429.pub5-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2450\/2019.0040-19","article-title":"Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE study","volume":"18","author":"Zanon","year":"2020","journal-title":"Blood Transfusion"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003429.pub5-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/hae.12400","article-title":"Standard prophylaxis vs on-demand treatment for children with severe hemophilia A: comparison of bleeding events in Chinese patients with hemophilia","volume":"20","author":"Zhao","year":"2014","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1080\/08880018.2017.1313921","article-title":"Efficacy of standard prophylaxis versus on-demand treatment with Bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A","volume":"34","author":"Zhao","year":"2017","journal-title":"Pediatric Hematology and Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.1976.tb00973.x","article-title":"Prophylaxis in haemophilia: a double blind controlled trial","volume":"33","author":"Aronstam","year":"1976","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/jcp.30.1.65","article-title":"Twice weekly prophylactic therapy in haemophilia A","volume":"30","author":"Aronstam","year":"1977","journal-title":"Journal of Clinical Pathology"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"489","DOI":"10.12688\/f1000research.12491.1","article-title":"Emerging therapies for hemophilia: controversies and unanswered questions","volume":"7","author":"Arruda","year":"2018","journal-title":"F1000 Research"},{"issue":"11","key":"10.1002\/14651858.CD003429.pub5-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003429.pub5-BIB0086|cit86","first-page":"16","article-title":"Clinical experience of pharmacokinetic dosing of factor VIII for prophylaxis","volume":"2","author":"Carlsson","year":"1996","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD003429.pub5-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"647","DOI":"10.18553\/jmcp.2023.29.6.647","article-title":"Health care costs and resource use of managing hemophilia A: a targeted literature review","volume":"29","author":"Chen","year":"2023","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40273-017-0588-z","article-title":"Modern treatments of haemophilia: review of cost-effectiveness analyses and future directions","volume":"36","author":"Cortesi","year":"2018","journal-title":"PharmacoEconomics"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0089|cit89","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2023"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/JBM.S363028","article-title":"The impact of pharmacokinetic-guided prophylaxis on clinical outcomes and healthcare resource utilization in hemophilia A patients: real-world evidence from the CHESS II study","volume":"13","author":"Grazzi","year":"2023","journal-title":"Journal of Blood Medicine"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0091|cit91","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.2.0"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0092|cit92","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.1"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0093|cit93","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.1"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0094|cit94","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0095|cit95","unstructured":"Plot Digitizer 2.6.9 Huwaldt JA Steinhorst S Source Forge 2020"},{"issue":"4","key":"10.1002\/14651858.CD003429.pub5-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4097\/kja.21165","article-title":"Considerations for crossover design in clinical study","volume":"74","author":"Lim","year":"2021","journal-title":"Korean Journal of Anesthesiology"},{"issue":"6","key":"10.1002\/14651858.CD003429.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7196\/SAMJ.2022.v112i6.16362","article-title":"Prophylaxis is the new standard of care in patients with haemophilia","volume":"112","author":"Mahlangu","year":"2022","journal-title":"South African Medical Journal"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0098|cit98","unstructured":"Mehta P Reddivari AK Hemophilia StatPearls 2024 (Internet) http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551607\/ https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551607\/"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003429.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1355-0691.2004.00880.x","article-title":"Setting research priorities to improve cost-effectiveness estimations of primary prophylaxis with clotting factor for people with severe haemophilia A","volume":"10","author":"Miners","year":"2004","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD003429.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1365-2516.2009.02019.x","article-title":"Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A","volume":"15","author":"Miners","year":"2009","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0609.1976.tb01115.x","article-title":"Evaluation of prophylactic replacement therapy in haemophilia B","volume":"16","author":"Morfini","year":"1976","journal-title":"Scandinavian Journal of Haematology"},{"issue":"15","key":"10.1002\/14651858.CD003429.pub5-BIB0102|cit102","first-page":"e41410","article-title":"Management of severe hemophilia A: low-dose prophylaxis vs. on-demand treatment","volume":"5","author":"Munawar Ali","year":"2023","journal-title":"Cureus"},{"issue":"5","key":"10.1002\/14651858.CD003429.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/hae.13589","article-title":"Value of prophylaxis vs on-demand treatment: application of a value framework in hemophilia","volume":"24","author":"Nugent","year":"2018","journal-title":"Haemophilia"},{"issue":"8","key":"10.1002\/14651858.CD003429.pub5-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014544","article-title":"Non-clotting factor therapies for preventing bleeds in people with hemophilia","author":"Olasupo","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003429.pub5-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014544.pub2","article-title":"Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B","author":"Olasupo","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3 Suppl 2","key":"10.1002\/14651858.CD003429.pub5-BIB0106|cit106","first-page":"7","article-title":"Radiographic scores and implications","volume":"30","author":"Pettersson","year":"1993","journal-title":"Seminars in Hematology"},{"issue":"4","key":"10.1002\/14651858.CD003429.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2516.2006.01292.x","article-title":"The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia","volume":"12","author":"Pollak","year":"2006","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/hematolrep15010014","article-title":"Haemophilia A: a review of clinical manifestations, treatment, mutations, and the development of inhibitors","volume":"15","author":"Sarmiento Doncel","year":"2023","journal-title":"Hematology Reports"},{"issue":"5","key":"10.1002\/14651858.CD003429.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/17474086.2019.1604213","article-title":"An update on the 'danger theory' in inhibitor development in hemophilia A","volume":"12","author":"Schep","year":"2019","journal-title":"Expert Review of Hematology"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"Suppl 6","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD003429.pub5-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/hae.12330","article-title":"Chinese Hemophilia Joint Health Score 2.1 reliability study","volume":"20","author":"Sun","year":"2014","journal-title":"Haemophilia"},{"issue":"7","key":"10.1002\/14651858.CD003429.pub5-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"632","DOI":"10.18553\/jmcp.2018.24.7.632","article-title":"Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia","volume":"24","author":"Thorat","year":"2018","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"10.1002\/14651858.CD003429.pub5-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"9","key":"10.1002\/14651858.CD003429.pub5-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003429.pub4","article-title":"Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B","author":"Iorio","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD003429.pub5-BIB0115|cit115","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014201","article-title":"Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B","author":"Olasupo","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003429.pub5-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003429","article-title":"Clotting factor concentrates given to prevent bleeding and bleeding related complications in people with hemophilia A and B","author":"Stobart","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003429.pub5-BIB0117|cit117","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003429.pub2","article-title":"Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B","author":"Stobart","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003429.pub5-BIB0118|cit118","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003429.pub3","article-title":"Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B","author":"Stobart","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:17:42Z","timestamp":1785910662000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003429.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":118,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003429.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}